Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2012/02/002434
CTRI/2012/02/002434
Completed
Phase 4

To assess the Efficacy, Quality of life and Safety of Image Blanc as a Complexion Lightener / Spot Lightener for the face and neck.

Glenmark Pharmaceuticals Ltd0 sites20 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Glenmark Pharmaceuticals Ltd
Enrollment
20
Status
Completed
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Pms

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Subjects with hyper pigmentation/dark spots of the face and neck.
  • •Age group: 30 years and above
  • •Willing to restrain from prolonged exposure to the sun for the length of the study
  • •Available for the entire duration of the study

Exclusion Criteria

  • •Hypersensitivity to any ingredients
  • •Pregnant and lactating women.
  • •Subjects who are already applying anti\-aging, skin lightening or AHA (Alpha hydroxy acids) based or retinol based cosmetics or have applied any of these in the last 3 months.
  • •Subjects with dermatological disorder of face that may interfere with study evaluation.
  • •Subjects who have undergone any surgical treatment of the face.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 4
To assess the efficacy of anti-wrinkle products.Health Condition 1: null- Wrinkles on face and neck
CTRI/2012/04/002551Glenmark Pharmaceuticals Limited100
Unknown
Not Applicable
STUDY OF THE EFFICACY, SAFETY AND QUALITY OF LIFE AFTER TOOKAD® SOLUBLE VASCULAR TARGETED PHOTODYNAMIC THERAPY (VTP) FOR MINIMALLY INVASIVE TREATMENT OF LOCALIZED PROSTATE CANCER.
PER-046-13Steba biotech S.A,18
Recruiting
Phase 2
Comparison of the efficacy of botulinum toxin and triamcinolone in patients with hypertrophic scars treated with PDL laser
IRCT20220121053776N1Iran University of Medical Sciences12
Active, not recruiting
Phase 1
A study of efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with Aerius tablets (5 mg, 10 mg or 20 mg once daily). - ACCEchronic idiopathic urticariaMedDRA version: 6.1 Level: PT Classification code 10021247
EUCTR2006-001449-33-ITSCHERING-PLOUGH600
Recruiting
Not Applicable
To evaluate the efficacy, safety and QOL(quality of life) of blonanserin monotherapy in schizophrenia patientsMental and behavioral disorders
KCT0001105Koera University Guro Hospital100